Upon approval, your medication arrives at your doorstep, paired with enduring provider support
Emerging data suggest that glucagonlike peptide1 receptor agonists (GLP1 RAs), originally developed for glycemic control and weight management, may have direct hepatic benefits even in patients who are not visibly obese or overtly diabetic
These events are as follows: cardiomyopathy, mydriasis, diplopia, difficulties with visual accommodation, blurred vision, eosinophilic hepatitis, anaphylactic reaction, hypersensitivity, dyskinesia, dysgeusia, motor and verbal tics, bruxism, depression, dermatillomania, alopecia, aggression, Stevens-Johnson Syndrome, chest pain, angioedema, urticaria, seizures, libido changes, frequent or prolonged erections, constipation, rhabdomyolysis, and intestinal ischemia
At the starting dose of 0.25 mg weekly, one vial contains 20 doses (20 weeks)